Stem Cell Manufacturing Market Trends, Share, Demand, Scope, Forecast 2030: SPER Market Research

Published: Apr 2022	Report ID: BIOT2220	Pages: 1 - 236	Formats^*:
Category : Biotechnology

Global Stem Cell Manufacturing Market Overview:

According to SPER Market Research, the Stem Cell Manufacturing Market estimated to reach USD 24.77 billion by 2030 with a CAGR of 8.9%. Encouraging regulatory framework, increasing investments in stem cell-based research, and growing alertness regarding the therapeutic potency of stem cell products; are the fuels for the escalation of the market.

Impact of COVID-19 on the Stem Cell Manufacturing Market

The outbreak of COVID-19; lead to lockdown globally, in turn negatively impacted the stem cell manufacturing market.

Scope of the report:

Report Metric	Details
Market size available for years	2019-2030
Base year considered	2021
Forecast period	2022-2030
Segments covered	By Product, By Application, By End-User, By Region
Geographies covered	North America, Europe, Asia Pacific, Latin America , Middle East, Africa
Companies Covered	Anterogen, Becton, Bio-Rad Laboratories, Bio-Techne Corporation, Cellgenix GMBH, Corning Inc., Danaher Corporation, Dickinson and Company, Eppendorf AG, Fujifilm Holdings Corporation, Getinge, Himedia Laboratories, Lonza Group AG, Merck Millipore, Miltenyi Biotec, Promocell, Sartorius AG, Stemcell Technologies, Takara Bio Group, Terumo BCT Inc., Thermo Fisher Scientific.

Driver: increasing venture capital investments in stem cell research

The increase in the public-private partnership investment in research for developing stem cell based technology. Stem cells are effective in disease management, personalized medicine and genomic testing.

Restraint: operational costs allied with stem cell manufacturing and banking

Expert techniques are used for stem cell isolation, purification, and storage. High operational cost coupled with stem cell manufacturing. Therefore, stem cell products are frequently available at a higher price than pharmaceutical drugs and biologics.

Opportunity: encouraging regulatory framework across developing countries

Regulatory reforms in the stem cell industries by the emerging countries meant for commercialization and research allied to stem cell therapy. Encouraging regulatory frameworks across developing countries are anticipated to offer huge opportunities to players in the market.

Challenges:

Technical limitations coupled with manufacturing scale-up, Socio-ethical concerns associated to the use of allogeneic and human embryonic stem cells; are the challenges to the market.

Global Stem Cell Manufacturing Market Segmentation:

By Product: Based on the Product, Global Stem Cell Manufacturing Market is segmented as; Consumables (Culture Media, Other Consumables), Instruments (Bioreactors and Incubators, Cell Sorters, Other Instruments), Stem Cell Lines [Embryonic stem cells (ESC), Hematopoietic stem cells (HSC), Induced Pluripotent Stem cells (iPSC), Mesenchymal stem cells (MSC), Multipotent adult progenitor stem cells, Neural Stem cells (NSC)].

By Application: Based on the Application, Global Stem Cell Manufacturing Market is segmented as; Research Applications (Life science research, Drug discovery and development), Clinical Application (Allogenic stem cell therapy, Autologous stem cell therapy), Cell & Tissue Banking Applications.

By End-User: Based on the End-User, Global Stem Cell Manufacturing Market is segmented as; Pharmaceutical & Biotechnology Companies, Academic institutes, Research laboratories & contract research organizations, Hospitals & surgical centers, Cell & tissue banks, Other End Users.

By Region: North America dominates the prime share of the stem cell manufacturing market; and this is due to the public-private funding and grants, extensive in progress stem cell research activities and support for the clinical evaluation of stem cells.

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source

2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPERâ€™s internal database
2.1.4 Premium insight from KOLâ€™s

2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges

4.2. COVID-19 Impacts of the Stem Cell Manufacturing Market

5. Market variables and outlook

5.1. SWOT analysis

5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats

5.2. PESTEL analysis

5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape

5.3. PORTERâ€™S five forces analysis

5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry

5.4. Heat map analysis

6. Global Stem Cell Manufacturing Market, By Product, 2019-2030 (USD Million)

6.1. Consumables

6.1.1. Culture Media
6.1.2. Other Consumables

6.2. Instruments

6.2.1. Bioreactors and Incubators
6.2.2. Cell Sorters
6.2.3. Other Instruments

6.3. Stem Cell Lines

6.3.1 Embryonic stem cells (ESC)
6.3.2 Hematopoietic stem cells (HSC)
6.3.3 Induced Pluripotent Stem cells (iPSC)
6.3.4 Mesenchymal stem cells (MSC)
6.3.5 Multipotent adult progenitor stem cells
6.3.6 Neural Stem cells (NSC)

7. Global Stem Cell Manufacturing Market, By Application, 2019-2030 (USD Million)

7.1. Research Applications

7.1.1. Life science research
7.1.2. Drug discovery and development

7.2. Clinical Application

7.2.1. Allogenic stem cell therapy
7.2.2. Autologous stem cell therapy

7.3. Cell & Tissue Banking Applications

8. Global Stem Cell Manufacturing Market, By End-User, 2019-2030 (USD Million)

8.1. Academic institutes, Research laboratories & contract research organizations
8.2. Cell & tissue banks
8.3. Hospitals & surgical centres
8.4. Other End Users
8.5. Pharmaceutical & Biotechnology Companies

9. Global Stem Cell Manufacturing Market, By Region, 2019-2030 (USD Million)

9.1. North America

9.1.1. United States
9.1.2. Canada
9.1.3. Mexico

9.2. Europe

9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific

9.4. South America

9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America

9.5. Middle East & Africa

9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa

10. Company Profiles

10.1. Anterogen

10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments

10.2. Becton

10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments

10.3. Bio-Rad Laboratories

10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments

10.4. Bio-Techne Corporation

10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments

10.5. Cellgenix GMBH

10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments

10.6. Corning Inc.

10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments

10.7. Danaher Corporation

10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments

10.8. Dickinson and Company

10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments

10.9. Eppendorf AG

10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments

10.10. Fujifilm Holdings Corporation

10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments

10.11. Getinge

10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments

10.12. Himedia Laboratories

10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments

10.13. Lonza Group AG

10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments

10.14. Merck Millipore

10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments

10.15. Miltenyi Biotec

10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments

10.16. Promocell

10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments

10.17. Sartorius AG

10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments

10.18. Stemcell Technologies

10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments

10.19. Takara Bio Group

10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments

10.20. Terumo BCT Inc.

10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments

10.21. Thermo Fisher Scientific

10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1